Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Patients who have had or are expected to have a poor ovarian response (POR), because they
meet any of the criteria of Bologna, can benefit from ovarian stimulation with 150 mg of
alpha Corifollitropin (CFA) (Elonva ®) as single dose for a week, in the cycles of in vitro
fertilization (IVF).
In this study aims to demonstrate non-inferiority of the Corifollitropin Alpha (CFA ) versus
daily administration of Human Menopausal Gonadotropin (hMG) (Menopur ®) during the first
seven days of ovarian stimulation, in a protocol with gonadotropin-releasing hormone ( GnRH)
antagonists